Page not found

Integrative Physiology & Pharmacology Ph.D. Program at Wake Forest University

Wake Forest University Graduate School » Integrative Physiology & Pharmacology Ph.D. Program

Karl-Erik Andersson, M.D., Ph.D.

Karl-Erik Andersson, M.D., Ph.D.
Dr. Karl-Erik Andersson was born and raised in Sweden. He received his medical degree from the University of Lund in 1968, where he subsequently worked as a lecturer in Clinical Pharmacology. He completed his Ph.D. at the Department of Pharmacology, Lund University, in 1973. In 1975 he obtained a Swedish specialist degree in Internal Medicine and was appointed as Professor of Clinical Pharmacology at the University of Odense, Denmark. From 1976 to 1978 he had the same position at the University of Aarhus, Denmark. From 1978-2006 he was Professor and Chairman of the Department of Clinical Pharmacology, University of Lund, Lund, Sweden. He has been visiting professor at the Department of Obstetrics and Gynaecology, University of Toronto (1983-1985) and at the Department of Urology, University of Virginia, Charlottesville, USA (1997-1998). From 1993 to 2000 Dr. Andersson was elected Research Dean of the Medical Faculty at the University of Lund. He is a member of many international societies including the American Urological Association, the European Association of Urology, and the International Society for Sexual and Impotence Research. He also serves on the Editorial Boards of several journals including Urology, European Urology, Neurourology and Urodynamics, International Journal of Impotence Research, and British Journal of Pharmacology. During his career, Dr. Andersson has authored more than 700 articles in peer-reviewed international journals. SYNOPSIS OF AREA OF INTEREST: Dr. Andersson's research interests include urogenital and cardiovascular pharmacology and physiology, clinical trials and regenerative pharmacology. DETAILED AREA OF INTEREST: Disturbances in urogenital tract function are common, and often based on malfunction of nerves and smooth muscle. Overactive bladder (OAB) syndrome is one of the most common disorders, and symptoms increase with age. OAB is also common in diabetes and neurological disease. Current drugs for treatment of OAB are limited by insufficient efficacy and side-effects, and new approaches are needed. This implies the search for new targets to pharmacologically control bladder function. Erectile dysfunction (ED) is age-related and is found in 30% of men over 60 years. Although sildenafil is efficacious in the treatment for ED, limitations are noted in patient-categories such as diabetes and cardiovascular disease, where ED also is more prevalent. At the Wake Forest Institute for Regenerative Medicine, the peripheral mechanisms involved in bladder overactivity and ED and afferent neuronal functions involved in the regulation of bladder and erectile functions are studied to improve drug therapies and/or to identify new targets for pharmacological treatment of urinary incontinence. A wide variety of molecular biological techniques, functional in vitro methods, and in vivo models are used. These methods will also be applied to characterize pharmacological and physiological properties of engineered tissues in vitro and in vivo, with the purpose of identifying targets to pharmacologically modify their function.


Andersson KE. Muscarinic acetylcholine receptors in the urinary tract. Handb Exp Pharmacol. 2011; 202():319-344.
Kurizaki Y, Ishizuka O, Imamura T, Ichino M, Ogawa T, Igawa Y, Nishizawa O, Andersson K-E. Relation between expression of alpha1-adrenoceptor mRNAs in bladder mucosa and urodynamic findings in men with lower urinary tract symptoms. Scand J Urol Nephrol. 2011; 45(1):15-19.
Thuroff JW, Abrams P, Andersson K-E, Artibani W, Chapple CR, Drake MJ, Hampel C, Neisius A, Schroder A, Tubaro A. EAU guidelines on urinary incontinence. Eur Urol. 2011; 59(3):387-400.
Gratzke C, Streng T, Stief CG, Alroy I, Limberg BJ, Downs TR, Rosenbaum JS, Hedlund P, Andersson K-E. Cannabinor, a selective cannabinoid-2 receptor agonist, improves bladder emptying in rats with partial urethral obstruction. J Urol. 2011; 185(2):731-736.
Campeau L, Gorbachinsky I, Ziegler JT, Langefeld CD, Andersson KE, Rohozinski J, Badlani G. Comparison of MMP-1 enzymatic activity and TIMP-1 inhibition in women with pelvic organ prolapse [abstract]. Neurourol Urodyn. 2011; 30(2):240-241.
Russo A, Castiglione F, Salonia A, Benigni F, Rigatti P, Montorsi F, Andersson K-E, Hedlund P. Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E2-induced detrusor overactivity in conscious female rats. Eur Urol. 2011; 59(5):868-874.
Abdel-Hamid IA, Andersson KE, Salonia A. Exploration of therapeutic targets for sexual dysfunctions: lessons learned from the failed stories. Expert Opin Ther Targets. 2011; 15(3):325-340.
Soler R, Fullhase C, Santos C, Andersson K-E. Development of bladder dysfunction in a rat model of dopaminergic brain lesion. Neurourol Urodyn. 2011; 30(1):188-193.
Streng T, Andersson KE, Hedlund P, Gratzke C, Baroni E, D'Ambrosio D, Benigni F. Elocalcitol improves effects by tolterodine in rats with partial urethral obstruction [abstract]. Eur Urol Suppl. 2011; 10(2):181-182.
Russo A, Castiglione F, Salonia A, Benigni F, Andersson KE, Hedlund P. Effects by the GNRH antagonist ganirelix on normal micturition and PGE2-induced detrusor overactivity in conscious female rats [abstract]. Eur Urol Suppl. 2011; 10(2):256-257.
Andersson K-E, de Groat WC, McVary KT, Lue TF, Maggi M, Roehrborn CG, Wyndaele JJ, Melby T, Viktrup L. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011; 30(3):292-301.
Aizawa N, Igawa Y, Andersson K-E, Iijima K, Nishizawa O, Wyndaele J-J. Effects of intravesical instillation of ATP on rat bladder primary afferent activity and its relationship with capsaicin-sensitivity. Neurourol Urodyn. 2011; 30(1):163-168.
Andersson K-E. Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol. 2011; 59(3):377-386.
Soler R, Fullhase C [Fuellhase C], Lu B, Bishop CE, Andersson K-E. Bladder dysfunction in a new mutant mouse model with increased superoxide--lack of nitric oxide?. J Urol. 2010; 183(2):780-785.
Gratzke C, Streng T, Stief CG, Downs TR, Alroy I, Rosenbaum JS, Andersson K-E, Hedlund P. Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats. Eur Urol. 2010; 57(6):1093-1100.
Russo A, Castiglione F, Andersson KE, Gustafsson JA, Hedlund P. Nitric oxide-, CGMP- & PGK1-mediated relaxation of the mouse vagina is coupled to the alpha estrogen receptor [abstract]. J Sex Med. 2010; 7(Suppl 3):130.
Burnett AL, Goldstein I, Andersson KE, Argiolas A, Christ G, Park K, Xin ZC. Future sexual medicine physiological treatment targets. J Sex Med. 2010; 7(10):3269-3304.
Montorsi F, Adaikan G, Becher E, Giuliano F, Khoury S, Lue TF, Sharlip I, Althof SE, Andersson KE, Brock G, et al. Summary of the recommendations on sexual dysfunctions in men. J Sex Med. 2010; 7(11):3572-3588.
Limberg BJ, Andersson K-E, Kullmann FA, Burmer G, de Groat WC, Rosenbaum JS. Beta-adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. Cell Tissue Res. 2010; 342(2):295-306.
Burmeister D, AbouShwareb T, Tan J, Link K, Andersson K-E, Christ G. Early stages of in situ bladder regeneration in a rodent model. Tissue Eng Part A. 2010; 16(8):2541-2551.
Chen Z, Ishizuka O, Imamura T, Aizawa N, Kuriazki Y, Igawa Y, Nishizawa O, Andersson K-E. Stimulation of skin menthol receptors stimulates detrusor activity in conscious rats. Neurourol Urodyn. 2010; 29(3):506-511.
Kanai A, Andersson K-E. Bladder afferent signaling: recent findings. J Urol. 2010; 183(4):1288-1295.
Christ GJ, Melman A, Williams K, Aboushwareb T, Zhao WX, Kaplan J, Anderson K-E [sic] [Andersson K-E]. Nonhuman primates as a model for translational research on atherosclerosis-related vascular disease and erectile dysfunction [abstract]. J Sex Med. 2010; 7(Suppl 1):46.
McKenzie P, Rohazinski J, Vishwajit S, Andersson K-E, Badlani G. Mmp-1 promoter variant is associated with stress urinary incontinence and pelvic organ prolapse [abstract]. Neurourol Urodyn. 2010; 29(2):255-256.
Andersson K-E. Detrusor myocyte activity and afferent signaling. Neurourol Urodyn. 2010; 29(1):97-106.
Weinhold P, Gratzke C, Streng T, Stief C, Andersson K-E, Hedlund P. TRPA1 receptor induced relaxation of the human urethra involves TRPV1 and cannabinoid receptor mediated signals, and cyclooxygenase activation. J Urol. 2010; 183(5):2070-2076.
Fullhase C, Soler R, Gratzke C, Brodsky M, Christ GJ, Andersson K-E. Spinal effects of the fesoterodine metabolite 5-hydroxymethyl tolterodine and/or doxazosin in rats with or without partial urethral obstruction. J Urol. 2010; 184(2):783-789.
Streng T, Santti R, Andersson K-E. Voiding effects mediated by alpha2-adrenoceptors in the anaesthetized male rat. BJU Int. 2010; 106(10):1546-1549.
Soler R, Fullhase C, Hanson A, Andersson K, Santos C. Effect of amniotic fluid and bone marrow stem cell therapy on bladder dysfunction in a Parkinson's disease model [abstract]. Int Urogynecol J. 2010; 21(Suppl 1):S384-S385.
Gratzke C, Weinhold P, Reich O, Seitz M, Schlenker B, Stief CG, Andersson K-E, Hedlund P. Transient receptor potential A1 and cannabinoid receptor activity in human normal and hyperplastic prostate: relation to nerves and interstitial cells. Eur Urol. 2010; 57(5):902-910.
Andersson K-E, Sarawate C, Kahler KH, Stanley EL, Kulkarni AS. Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder. BJU Int. 2010; 106(2):268-274.
Fullhase C, Soler R, Gratzke C, Brodsky M, Christ GJ, Andersson K-E. Urodynamic evaluation of fesoterodine metabolite, doxazosin and their combination in a rat model of partial urethral obstruction. BJU Int. 2010; 106(2):287-293.
Zhao W, Aboushwareb T, Turner C, Mathis C, Bennett C, Sonntag WE, Andersson K-E, Christ G. Impaired bladder function in aging male rats. J Urol. 2010; 184(1):378-385.
Fullhase C [Fuellhase C], Soler R, Lu B, Bishop CE, Andersson KE. Increased levels of superoxide ions affects bladder function in a new mutant mouse model [abstract]. Eur Urol Suppl. 2009; 8(4):176.
Kim J, Asche C, Kahler K, Kulkarni A, Andersson KE. Assessment of cardiovascular (CV) comorbidity in patients with overactive bladder (OAB) [abstract]. Pharmacoepidemiol Drug Saf. 2009; 18(Suppl 1):S241-S242.
Werkstrom V, Hedlund P, Lee T, Andersson K-E. Vardenafil-induced relaxation and cyclic nucleotide levels in normal and obstructed rat urinary bladder. BJU Int. 2009; 104(11):1740-1745.
Abdel-Hamid IA, Jannini EA, Andersson KE. Premature ejaculation: focus on therapeutic targets. Expert Opin Ther Targets. 2009; 13(2):175-193.
Gratzke C, Streng T, Waldkirch E, Sigl K, Stief C, Andersson K-E, Hedlund P. Transient receptor potential A1 (TRPA1) activity in the human urethra--evidence for a functional role for TRPA1 in the outflow region. Eur Urol. 2009; 55(3):696-704.
Soler R, Fullhase C [Fuellhase C], Santos CC, Vishwajit S, Badlani GH, Andersson K-E. Bladder dysfunction in an acute experimental model of unilateral dopaminergic neurons lesion [abstract]. J Urol. 2009; 181(4 Suppl):336.
Eberli D, Andersson KE, Yoo JJ, Atala A. A canine model of irreversible urethral sphincter insufficiency. BJU Int. 2009; 103(2):248-253.
Weinhold P, Gratzke C, Streng T, Andersson KE, Hedlund P. TRPA1-receptor-induced relaxation of the human urethra involves TRPV1-and cannabinoid-receptor-mediated signals and activation of cyclooxygenases [abstract]. Eur Urol Suppl. 2009; 8(4):270.
Imamura T, Ishizuka O, Zhong C, Ogawa T, Nakayama T, Kurizaki Y, Tanabe T, Nishizawa O, Andersson K-E. An extract (THC-002) of Ba-Wei-Die-Huang-Wan inhibits expression of tachykinins, and P2X3 and TRPV1 receptors, and inhibits ATP-induced detrusor overactivity in spontaneously hypertensive rats. Neurourol Urodyn. 2009; 28(6):529-534.
Aizawa N, Iijima K, Rosenbaum J, Downs TR, Igawa Y, Andersson K, Wyndaele JJ. Effects of estrogen deficiency and its replacement on voiding behaviour and primary bladder afferent activity in the rat [abstract]. Neurourol Urodyn. 2009; 28(7):800-802.
Fuellhase C, Soler R, Andersson KE, Atala A, Yoo JJ. Generation of organized bladder tissue constructs using a novel hybrid printing system [abstract]. Eur Urol Suppl. 2009; 8(4):186.
Gratzke C, Weinhold P, Reich O, Stief CG, Andersson KE, Hedlund P. Distribution and function of transient receptor potential ion channel A1 and cannabinoid receptors in the human prostate [abstract]. Eur Urol Suppl. 2009; 8(4):190.
Weinhold P, Hedlund P, Reich O, Stief CG, Andersson KE, Gratzke C. Transient receptor potential A1 (TRPA1) agonists decrease nerve-mediated responses of the human ureter [abstract]. Eur Urol Suppl. 2009; 8(4):206.
Christ GJ, Andersson K-E, Williams K, Zhao W, D'Agostino R Jr, Kaplan J, Aboushwareb T, Yoo J, Calenda G, Davies KP, et al. Smooth-muscle-specific gene transfer with the human Maxi-K channel improves erectile function and enhances sexual behavior in atherosclerotic cynomolgus monkeys. Eur Urol. 2009; 56(6):1055-1066.
Vishwajit S, Anderson KE [sic] [Andersson KE]. Terminology of lower urinary tract symptoms. Helpful or confusing?. ScientificWorldJournal. 2009; 9():17-22.
Gratzke C, Streng T, Park A, Christ G, Stief CG, Hedlund P, Andersson K-E. Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol. 2009; 181(4):1939-1948.
Vishwajit S, Rohozinski J, Andersson K-E, Badlani GH. Association of MMP1 promoter variant with stress urinary incontinence and pelvic organ prolapse in women [abstract]. J Urol. 2009; 181(4 Suppl):481.
Russo A, Castiglione F, Anderson KE [sic] [Andersson KE], Gustafsson JA, Hedlund P. Lack of estrogen receptor alpha alters nerve-mediated contraction and NO/cGMP-mediated relaxation of the mouse vagina [abstract]. J Sex Med. 2009; 6(Suppl 5):405-406.
Streng T, Hedlund H, Svalheim S, Talo A, Solend CM, Andersson KE, Hedlund P. Bladder electrical activity during cystometry: application from rat to human [abstract]. Eur Urol Suppl. 2009; 8(4):243.
Andersson KE. When and how do antimuscarinics work in bladder dysfunction, and what's coming up in treatment? [abstract]. Eur J Neurol. 2009; 16(Suppl 3):630.
Soler R, Fuellhase C, Andersson KE, Yoo JJ. The effect of lamina propria cells on the growth of urothelial and smooth muscle cells [abstract]. Eur Urol Suppl. 2009; 8(4):188.
Andersson KE, Chapple CR, Cardozo L, Cruz F, Hashim H, Michel MC, Tannenbaum C, Wein AJ. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence. Curr Opin Urol. 2009; 19(4):380-394.
Zhao W, Sato Y, Melman A, Andersson KE, Christ G. Metrics for evaluation of age-related changes in erectile capacity in a rodent model. J Sex Med. 2009; 6(7):1885-1892.
Jin L-H, Andersson K-E, Kwon Y-H, Park C-S, Yoon S-M, Lee T. Substantial detrusor overactivity in conscious spontaneously hypertensive rats with hyperactive behaviour. Scand J Urol Nephrol. 2009; 43():3-7.
Burmeister D, AbouShwareb T, Andersson K, Christ G. Establishing a rodent model for characterization of natural in vivo bladder regeneration [abstract]. Neurourol Urodyn. 2009; 28(7):739-741.
Ishizuka O, Chen Z, Imamura T, Aizawa N, Kurizaki Y, Igawa Y, Nishizawa O, Andersson K. Stimulation of cold stress skin receptor: transient receptor potential melastatin 8 (TRPM8) causes sudden urinary frequency in normal conscious rats [abstract]. Neurourol Urodyn. 2009; 28(7):750-752.
Andersson KE. Pharmacotherapy of the overactive bladder. Discov Med. 2009; 8(42):118-124.
Chen Z, Ishizuka O, Imamura T, Aizawa N, Igawa Y, Nishizawa O, Andersson K-E. Role of alpha1-adrenergic receptors in detrusor overactivity induced by cold stress in conscious rats. Neurourol Urodyn. 2009; 28(3):251-256.
Gratzke C, Weinhold P, Selwood D, Stief CG, Andersson KE, Hedlund P. Distribution of the G-protein-coupled receptor 55 (GPR55) in the rat bladder and urodynamic effects of a selective GPR55-agonist in conscious rats [abstract]. Eur Urol Suppl. 2009; 8(4):271.
Aboushwareb T, Zhou G, Deng F-M, Turner C, Andersson K-E, Tar M, Zhao W, D'Agostino R Jr, Sun T-T, Christ GJ, et al. Alterations in bladder function associated with urothelial defects in uroplakin II and IIIa knockout mice. Neurourol Urodyn. 2009; 28(8):1028-1033.
Soler R, Fuellhase C, Lu B, Bishop C, Andersson K. Bladder dysfunction in a new animal model of increased levels of superoxide ions [abstract]. Neurourol Urodyn. 2009; 28(7):809-810.
Abdel-Hamid IA, Andersson KE. Pharmacogenetics and pharmacogenomics of sexual dysfunction: current status, gaps and potential applications. Pharmacogenomics. 2009; 10(10):1625-1644.
Hipp JA, Hipp JD, Yoo JJ, Atala A, Andersson KE. Micro array analysis of bladder smooth muscle from patients with myelomeningocele [abstract]. Eur Urol. 2008; 7(3):229.
Ney P, Pandita RK, Newgreen DT, Breidenbach A, Stohr T, Andersson K-E. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int. 2008; 101(8):1036-1042.
Hipp JA, Hipp JD, Yoo JJ, Atala A, Andersson KE. Microarray analysis of bladder smooth muscle from patients with myelomeningocele. BJU Int. 2008; 102(6):741-746.
Gratzke C, Christ GJ, Kaplan JR, Andersson K-E, Badlani G. Chronic soy and phytoestrogen treatment leads to significant functional and morphological changes in the urethra of female non-human primates [abstract]. Neurourol Urodyn. 2008; 27(2):106.
Gratzke C, Jarajapu YPR, Christ GJ, Kaplan JR, Williams JK, Andersson K-E, Badlani G. Effects of long-term dietary soy treatment on female urethral morphology and function in ovariectomized nonhuman primates. J Urol. 2008; 180(5):2247-2253.
Delo DM, Eberli D, Williams JK, Andersson K-E, Atala A, Soker S. Angiogenic gene modification of skeletal muscle cells to compensate for ageing-induced decline in bioengineered functional muscle tissue. BJU Int. 2008; 102(7):878-884.
Gratzke C, Christ GJ, Kaplan JR, Stief CG, Andersson KE, Badlani G. Chronic soy and phytoestrogen treatment leads to significant functional and morphological changes in the urethra of oophorectomized female non-human primates [abstract]. Eur Urol. 2008; 7(3 Suppl):315.
Zhang Y, McNeill E, Tian H, Soker S, Andersson K-E, Yoo JJ, Atala A. Urine derived cells are a potential source for urological tissue reconstruction. J Urol. 2008; 180(5):2226-2233.
Streng T, Axelsson HE, Hedlund P, Andersson DA, Jordt S-E, Bevan S, Andersson K-E, Hogestatt ED, Zygmunt PM. Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur Urol. 2008; 53(2):391-400.
Christ GJ, Andersson K-E, Williams K, Zhao W, D'Agostino R, Kaplan J, Aboushwareb T, Yoo J, Davies K, Melman A. MAXI-K gene transfer with a smooth muscle specific promoter enhances erectile function and sexual behaviour in atherosclerotic cynomolgous monkeys [abstract]. Eur Urol. 2008; 7(3 Suppl):143.
Lu B, Poirier C, Gaspar T, Gratzke C, Harrison W, Busija D, Matzuk MM, Andersson K-E, Overbeek PA, Bishop CE. A mutation in the inner mitochondrial membrane peptidase 2-like gene (Immp2l) affects mitochondrial function and impairs fertility in mice. Biol Reprod. 2008; 78(4):601-610.
Gomez-Pinilla PJ, Gomez MF, Sward K, Hedlund P, Hellstrand P, Camello PJ, Andersson K-E, Pozo MJ. Melatonin restores impaired contractility in aged guinea pig urinary bladder. J Pineal Res. 2008; 44(4):416-425.
Igawa Y, Aizawa N, Iijima K, Wyndaele JJ, Andersson K, Nishizawa O. Effects of intravesical capsaicin, resiniferatoxin and ATP on primary bladder afferent activity of the rat [abstract]. Neurourol Urodyn. 2008; 27(7 Suppl):709-711.
Hodges SJ, Zhou G, Deng F-M, Aboushwareb T, Turner C, Andersson K-E, Santago P, Case D, Sun T-T, Christ GJ. Voiding pattern analysis as a surrogate for cystometric evaluation in uroplakin II knockout mice. J Urol. 2008; 179(5):2046-2051.
Aizawa N, Ishizuka O, Ogawa T, Mizusawa H, Igawa Y, Nishizawa O, Andersson KE. Effects of natriuretic peptides on intracavernous pressure and blood pressure in conscious rats. J Sex Med. 2008; 5(10):2312-2317.
Andersson KE, Fullhase C [Fuellhase C], Soler R. Urothelial effects of oral agents for overactive bladder. Curr Urol Rep. 2008; 9(6):459-464.
Aboushwareb T, Burmeister D, Andersson KE, Christ GJ. Novel longitudinal studies of rat bladder regeneration [abstract]. Eur Urol Suppl. 2008; 7(3):266.
Werkstrom V, Lee T, Hedlund P, Andersson KE. Vardenafil relaxes precontracted rat detrusor partially through urothelium-dependent mechanisms [abstract]. Eur Urol. 2008; 7(3 Suppl):264.
Zhao W, Machigal M, Turner C, Davies K, Melman A, Andersson KE, Christ GJ. Threshold gene transfer with hSlo enhances sildenafil-induced erectile responses in 2-month streptozotocin (STZ)-diabetic rats [abstract]. Eur Urol. 2008; 7(3 Suppl):217.
Andersson K-E. How many drugs for LUTS due to BPH are too many? [editorial]. J Urol. 2008; 180(3):811-812.
Gratzke C, Streng T, Waldkirch E, Sigl K, Stief CG, Andersson K, Hedlund P. Transient receptor potential A1 (TRPA1) ion channel activity in the human urethra--evidence for a functional role for TRPA1 in the outflow region [abstract]. Neurourol Urodyn. 2008; 27(7 Suppl):599-600.
Andersson KE, Christ GJ. Regenerative pharmacology: the future is now. Mol Interv. 2007; 7(2):79-86.
Bivalacqua TJ, Kendirci M, Champion HC, Hellstrom WJG, Andersson K-E, Hedlund P. Dysregulation of cGMP-dependent protein kinase 1 (PKG-1) impairs erectile function in diabetic rats: influence of in vivo gene therapy of PKG1alpha. BJU Int. 2007; 99(6):1488-1494.
Hipp J, Andersson K-E, Kwon TG, Kwak EK, Yoo J, Atala A. Microarray analysis of exstrophic human bladder smooth muscle. BJU Int. 2007; 101(1):100-105.
Andersson K, Kahler K, Ebinger U. Prevalence of cardiovascular co-morbidities in patients treated with antimuscarinics for overactive bladder (OAB) [abstract]. Neurourol Urodyn. 2007; 26(5):653-654.
Andersson K, Kahler K, Ebinger U. Heart rates in OAB patients prior to initiation of treatment with antimuscarinics [abstract]. Neurourol Urodyn. 2007; 26(5):654-655.
Aboushwareb T, Zho G, Turner C, Andersson K-E, Tar M, Melman A, Deng F-M, Sun T-T, Christ GJ. Urodynamic characterization of mice lacking uroplakin II or III [abstract]. FASEB J. 2007; 21(6):A1308.
Hedlund P, Streng T, Lee T, Andersson K-E. Effects of tolterodine on afferent neurotransmission in normal and resiniferatoxin treated conscious rats. J Urol. 2007; 178(1):326-331.
Andersson KE, Uckert S, Stief C, Hedlund P. Phosphodiesterases (PDEs) and PDE inhibitors for treatment of LUTS. Neurourol Urodyn. 2007; 26(Suppl 6):928-933.
Andersson KE. LUTS treatment: future treatment options. Neurourol Urodyn. 2007; 26(Suppl 6):934-947.
Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn. 2007; 26(Suppl 6):948-954.
Aboushwareb T, Jarajapu YPR, Blaha S, Hodges S, Turner C, Zhao W, Andersson K-E, Christ GJ. Mechanistic studies of detrusor over activity in male rats following partial urethral obstruction: implications to identification of novel therapeutics [abstract]. FASEB J. 2007; 21(6):A1356.
Aboushwareb T, Andersson K-E, Christ GJ. Pharmacological studies of AGI-1140 in a rat model of erectile dysfunction [abstract]. FASEB J. 2007; 21(6):A1159-1160.
Abrams P, Andersson K-E. Muscarinic receptor antagonists for overactive bladder. BJU Int. 2007; 100(5):987-1006.
Albrecht K, Uckert S, Oelke M, Andersson K-E, Jonas U, Troger H-D, Hedlund P. Immunohistochemical distribution of cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human vagina: a potential forensic value?. J Forensic Leg Med. 2007; 14(5):270-274.
Gomez-Pinilla PJ, Gomez MF, Hedlund P, Sward K, Hellstrand P, Camello PJ, Pozo MJ, Andersson K-E. Effect of melatonin on age associated changes in guinea pig bladder function. J Urol. 2007; 177(4):1558-1561.
Hodges S, Zhou G, Deng F-M, Abouschwareb T, Turner C, Andersson K-E, Santago P, Sun H, Christ GJ. Voiding patterns in uroplakin II knockout mice [abstract]. FASEB J. 2007; 21(6):A1301.
Sjoqvist F, Eriksson L-O, Andersson K-E. Merck fellowships contribute to the continued growth of clinical pharmacology in Sweden. Eur J Cln Pharmacol. 2007; 63(3):229-231.
Aboushwareb TA, Zhou G, Turner C, Andersson KE, Tar M, Melman A, Deng FM, Sun TT, Christ GJ. Urodynamic studies in uroplakin II or III knockout (KO) mice [abstract]. J Urol. 2007; 177(4 Suppl):88.
Waldkirch ES, Uckert S, Langnase K, Richter K, Jonas U, Wolf G, Andersson K-E, Stief CG, Hedlund P. Immunohistochemical distribution of cyclic GMP-dependent protein kinase-1 in human prostate tissue. Eur Urol. 2007; 52(2):495-502.
Lee T, Hedlund P, Newgreen D, Andersson K-E. Urodynamic effects of a novel EP1 receptor antagonist in normal rats and rats with bladder outlet obstruction. J Urol. 2007; 177(4):1562-1567.
Zhao W, Machingal M, Turner C, Davies K, Andersson K-E, Melman A, Christ GJ. Threshold gene transfer with hSlo enhances sildenafil-induced erectile responses in 2 month streptozotocin(STZ)-diabetic rats [abstract]. FASEB J. 2007; 21(5):A420.
Lagou M, De Vente J, Kirkwood TB, Hedlund P, Andersson K-E, Gillespie JI, Drake MJ. Location of interstitial cells and neurotransmitters in the mouse bladder. BJU Int. 2006; 97(6):1332-1337.
Schroder A, Colli E, Maggi M, Andersson K-E. Effects of a vitamin D3 analogue in a rat model of bladder outlet obstruction. BJU Int. 2006; 98(3):637-642.
Uckert S, Hedlund P, Andersson K-E, Truss MC, Jonas U, Stief CG. Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol. 2006; 50(6):1194-1207.
Oelke M, Hedlund P, Albrecht K, Ellinghaus P, Stief CG, Jonas U, Andersson K-E, Uckert S. Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris: immunohistochemical and molecular biology study. Urology. 2006; 67(5):1111-1116.
Abrams P, Andersson K-E, Buccafusco JJ, Chapple C, de Groat WC, Fryer AD, Kay G, Laties A, Nathanson NM, Pasricha PJ, et al. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol. 2006; 148(5):565-578.
Streng T, Hedlund P, Talo A, Andersson K-E, Gillespie JI. Phasic non-micturition contractions in the bladder of the anaesthetized and awake rat. BJU Int. 2006; 97(5):1094-1101.
Werkstrom V, Svensson A, Andersson K-E, Hedlund P. Phosphodiesterase 5 in the female pig and human urethra: morphological and funcitonal aspects. BJU Int. 2006; 98(2):414-423.
Uckert S, Oelke M, Stief CG, Andersson K-E, Jonas U, Hedlund P. Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol. 2006; 49(4):740-745.
Finney SM, Andersson K-E, Gillespie JI, Stewart LH. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?. BJU Int. 2006; 98(3):503-507.
Drake M, Gillespie J, Hedlund P, Harvey I, Lagou M, Andersson K-E. Muscarinic stimulation of the rat isolated whole bladder: pathophysiological models of detrusor overactivity. Auton Autacoid Pharmacol. 2006; 26(3):261-266.


Coming soon..........